Increased Emotional-motivational Processing in Patients with Chronic Pain and Its Neural Correlates
1 other identifier
interventional
138
1 country
1
Brief Summary
Chronic pain causes immense suffering and reductions in quality of life as well as enormous socioeconomic costs. Very many chronic pain patients fall into the category of unspecific pain, i.e. pain without clear medical explanation, with lacking effective treatments. It is assumed that a negative hedonic shift, characterized by excessive emotional-motivational processing and neg-ative affect, contributes causally to the development and maintenance of chronic pain. The mechanisms leading to such a shift are largely unclear; however, learning mechanisms appear likely candidates, possibly causing decreased connectivity in the fronto-striatal brain circuits. The project's over-all aim is to characterize mechanisms of emotional-motivational pain pro-cessing. The specific objectives are to illustrate that emotional-motivational pain components are heightened in chronic pain and that they can be de-creased by counterconditioning as an important and pervasive mechanisms in everyday life. Furthermore, its neural correlates in fronto-striatal networks underlying the conditioning effects will be characterized.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable chronic-pain
Started Apr 2022
Typical duration for not_applicable chronic-pain
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 3, 2022
CompletedFirst Posted
Study publicly available on registry
February 25, 2022
CompletedStudy Start
First participant enrolled
April 6, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 5, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 5, 2024
CompletedFebruary 11, 2025
September 1, 2024
2 years
February 3, 2022
February 7, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Successful Avoidance Responses
In Substudy1(b) and Substudy2: The number of successful avoidance responses upon correct discrimination responses in the task assessing sensory-discriminative and emotional-motivational pain responses simultaneously.
during the procedure
Fronto-striatal Networks
In Substudy 2: Blood oxygen level dependent (BOLD) signal and changes in functional connectivity in fronto-striatal networks while assessing sesnorydiscriminative and emotional-motivational pain responses simultaneously.
during the procedure
Secondary Outcomes (15)
Reaction Times (RT)
during the procedure
Pain Threshold in °C
baseline
Pain Tolerance in °C
baseline
Visual Analogue Scale (VAS) for Perceived Pain Intensity
during the procedure
Visual Analogue Scale (VAS) for Perceived Pain Unpleasantness
during the procedure
- +10 more secondary outcomes
Study Arms (2)
Chronic Pain Patients
EXPERIMENTALAll participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The performance of chronic pain patients will be compared to healthy volunteers to characterize possible alterations in patients. Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of pain, which is assumed to be already increased in patients. Primary objectives: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain, and that enhanced emotional-motivational pain responses in chronic pain can be decreased by counterconditioning, leading to a normalization of pain perception relative to healthy individuals. Secondary objective: Assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses.
Healthy Controls
EXPERIMENTALSubstudy 1(b): Participants perform 1 psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. Associative learning by monetary reinforcement is implemented to diminish the pain aversiveness. Substudy2: Participants perform the same task combined with MRI assessing the counterconditioning effects on frontostriatal circuits. Primary objective: Show that emotional-motivational components are increased relative to sensory-discriminative components in chronic pain (Substudy 1(b)). Assess the neural correlates of the counterconditioning effects on emotional-motivational pain responses, specifically alterations in functional connectivity in frontostriatal networks compared to the unchanged natural state (Substudy 2). Secondary objective: To assess whether chosen personality traits assessed by questionnaires can explain variations in sensory-discriminative and emotional-motivational pain responses (Substudy1(b)+2).
Interventions
Substudy 1(b): All participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously. The responses and the reaction times of chronic pain patients will be compared to those of healthy participants to characterize possible alterations in the patients (Substudy 1). Associative learning by monetary reinforcement will be implemented to diminish the aversiveness of the pain, which is assumed to be already increased in the patients. Substudy 2: As in Substudy 1, all participants will perform one psychophysical task to assess sensory-discriminative and emotional-motivational pain responses simultaneously combined with MRI assessing the effects of the counterconditioning on fronto-striatal circuits.
Eligibility Criteria
You may qualify if:
- Between 18 and 70 years of age (in Substudy 1: age- and sex-matched to chronic pain patients)
- Good overall health status
- Sufficient knowledge of German or English to follow instructions
- Ability to give written informed consent
You may not qualify if:
- Pain longer than \>3 consecutive days and on more than 30 days within the last 12 months
- Major psychiatric or neurological disorders, and substance abuse
- Consumption of alcohol, illegal drugs, and analgesic drugs within 24 hours before testing
- Pregnancy
- For Substudy 2: An MR-specific safety questionnaire will be filled in to check for any contradiction to magnetic resonance imaging (MRI): wearing an electronic device, implants or prosthetics, injury from metal parts or fragments, metal parts in or on the body, surgery on the head, heart or back, tattoo or permanent makeup, problems lying still for long periods of time, claustrophobia, possible pregnancy, metal contraceptive coil
- CHRONIC PAIN PATIENTS
- Between 18 and 70 years of age
- Unspecific musculoskeletal pain as defined according to the ICD-11 as chronic primary pain (MG30.1, e.g. chronic widespread pain, complex regional pain syndrome, chronic primary headache or orofacial pain, chronic migraine, chronic tension-type headache, trigeminal autonomic cephalalgias, burning mouth syndrome, chronic primary visceral pain, irritable bowel syndrome, chronic primary musculoskeletal pain), and which is not classified as chronic cancer related pain (MG30.2; e.g. chronic cancer pain, chronic post-cancer treatment pain), chronic postsurgical or post traumatic pain (MG30.3; e.g. chronic postsurgical pain, chronic posttraumatic pain), chronic secondary musculoskeletal pain (MG30.4; e.g. chronic musculoskeletal pain from persistent inflammation, chronic musculoskeletal pain associated with structural changes, chronic musculoskeletal pain associated with a disease of the nervous system), chronic secondary visceral pain (MG30.5; e.g. chronic visceral pain from persistent inflammation, chronic visceral pain from vascular mechanisms, chronic visceral pain from mechanical factors), chronic neuropathic pain (MG30.6; e.g. chronic peripheral neuropathic pain, trigeminal neuralgia, postherpetic neuralgia, chronic central neuropathic pain), chronic secondary headache or orofacial pain (MG30.7; e.g. chronic dental pain, chronic neuropathic orofacial pain, trigeminal neuralgia, headache or orofacial pain attributed to chronic secondary temporo-mandibular disorders), other specified chronic pain (MG30.Y), or other non-specified chronic pain (MG30.Z)
- Sufficient knowledge of German or English to follow instructions
- Ability to give written informed consent
- Major psychiatric or neurological disorders, and substance abuse
- Regular intake of opioids for pain (e.g. burprenorphine, codeine, fentanyl, hydromorphone, orphine, oxycodone, tapentadol, tilidine/na-loxone, tramadol)
- Consumption of alcohol, illegal drugs, and analgesic drugs within 24 hours before testing
- Pregnancy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- susanne beckerlead
- SNSFcollaborator
Study Sites (1)
Balgrist Campus
Zurich, Canton of Zurich, 8008, Switzerland
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Susanne Becker, Dr. Prof.
Balgrist Universitätsklinik
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Masking Details
- Participants are not fully instructed about the purpose before and during the test but will be debriefed after testing.
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Head of Research Group
Study Record Dates
First Submitted
February 3, 2022
First Posted
February 25, 2022
Study Start
April 6, 2022
Primary Completion
April 5, 2024
Study Completion
April 5, 2024
Last Updated
February 11, 2025
Record last verified: 2024-09
Data Sharing
- IPD Sharing
- Will not share